Provided is a thrombolytic agent for ‘intravascular thrombus’, and more particularly, to a thrombolytic agent having a thrombo-recognition domain and a thrombolytic domain. It also relates to a polypeptide for thrombolysis of an intravascular thrombus, a gene for that polypeptide, and a pharmaceutical composition containing the same. The polypeptide that recognizes ‘intravascular thrombus’ and dissolves thrombus of the present invention is characterized in that it consists of a thrombolytic domain comprising the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2 and a thrombo-recognition domain comprising the amino acid sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 4. According to the present invention, the polypeptide for dissolving thrombus by recognizing ‘intravascular thrombus’ dissolves thrombus in the blood of a mammal without serious bleeding side effects has a preventive and therapeutic effect on thrombosis, thus preventing thrombosis and related diseases.

A novel technique for reducing the mis-cleavage of the TorA signal peptide, and thereby a method for efficient secretory production of a heterologous protein by a coryneform bacterium using a TorA signal peptide is provided. A coryneform bacterium having an ability of secretory production of a heterologous protein using a TorA signal peptide and has been modified so that the activity of a LepB protein is increased is cultured to produce the heterologous protein by secretory production.

Provided herein are compounds that form covalent bonds with peptidases, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SPase), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.